REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can safely and effectively treat adults with diffuse large B-cell lymphoma that has come back or stopped responding to prior therapy. The drugs work by attaching to cancer cells and e…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 05:09 UTC
-
New drug may keep lymphoma in check long enough for Life-Saving cell therapy
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy in people with large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this bridging therapy can control the cancer long enough for patients to successfully unde…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 05:08 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to evaluate safety, the bes…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:07 UTC
-
Engineered immune cells take on HIV-Linked cancers
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 26, 2026 04:35 UTC